AI Article Synopsis
- The study investigates whether elevated levels of matrix metalloproteinase 9 (MMP9) in cerebrospinal fluid (CSF) are linked to poor treatment outcomes in patients with tuberculous meningitis.
- It assessed 40 HIV-negative tuberculous meningitis patients, finding that pretreatment MMP9 levels did not significantly differ between those with good and poor outcomes, despite correlations with CSF glucose and Glasgow coma scale scores.
- The conclusion indicates that higher pretreatment MMP9 levels do not predict poor treatment outcomes, contradicting the initial hypothesis.
Article Abstract
Objectives: Tuberculous meningitis is characterized by elevated levels of matrix metalloproteinase 9 (MMP9) in the cerebrospinal fluid (CSF). However, it is unclear whether elevated MMP9 levels are associated with poor treatment outcome. We tested the hypothesis that pretreatment MMP9 levels in the CSF would be higher in tuberculous meningitis patients experiencing a poor treatment outcome.
Methods: We prospectively assessed the treatment outcome in a consecutive sample of human immunodeficiency virus-negative patients with tuberculous meningitis. We defined good outcome as survival without severe neurological disability (modified Rankin scale scores 0-2). We estimated levels of MMP9 and its tissue inhibitor (TIMP1) on pretreatment CSF samples. We used albumin index to assess blood-brain barrier permeability.
Results: We studied 40 patients (23 males [58%]) with tuberculous meningitis. Sixteen patients (40%) had stage 3 disease. On follow-up, 18 (45%) patients had a poor treatment outcome-15 patients died and 3 had severe neurological disability. Pretreatment MMP9 levels were not associated with treatment outcome (median [interquartile range], 254 [115-389] vs. 192 [60-383] ng/mL in good vs. poor outcome groups; P = 0.693). MMP9 levels did not correlate with the albumin index (Spearman's rho = 0.142; P = 0.381). However, MMP9 levels significantly correlated with CSF glucose levels (rho = -0.419; P = 0.007) and admission Glasgow coma scale score (rho = 0.324; P = 0.032). Likewise, TIMP1 levels also did not differ by treatment outcome (1239 [889-1511] vs. 1522 [934-1949] ng/mL; P = 0.201). MMP9/TIMP1 ratio that reflects net proteolytic activity was also not different between the two groups (0.191 [0.107-0.250] vs. 0.163 [0.067-0.34]; P = 0.625).
Conclusion: Our findings do not support the hypothesis that pretreatment levels of MMP9 would be higher in tuberculous meningitis patients experiencing a poor treatment outcome. Further, MMP9 levels in the CSF did not correlate with blood-brain barrier permeability in patients with tuberculous meningitis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507543 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0181262 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Tuberculous meningitis-related ischemic stroke: A retrospective study from a tertiary care hospital.
J Clin Tuberc Other Mycobact Dis
February 2025
Department of Neurology, First Affiliated Hospital of Guangxi Medical University, China.
Background: Patients with tuberculous meningitis (TBM) are at high risk of ischemic stroke, and stroke is a poor prognosticator of TBM. However, reports regarding the predictors of stroke in TBM patients are scanty. The aim of this study was to investigate the clinical characteristics and predictors of tuberculous meningitis-related ischemic stroke (TBMRIS).
View Article and Find Full Text PDFChronic Myeloid Leukemia Presenting With Bilateral Optic Neuropathy and Sensorineural Hearing Loss as the First Clinical Presentation: A Case Report.
Case Rep Neurol Med
January 2025
Department of Pathology, Mayo Hospital, King Edward Medical University, Lahore, Pakistan.
Chronic myeloid leukemia (CML) is a myeloproliferative disorder that commonly manifests in chronic, accelerated, or blast phase. Typically observed in individuals aged 60-65 years, CML is infrequently diagnosed in adolescents. The usual presentation in late adulthood involves nonspecific symptoms such as fever, fatigue, and weight loss, with rare reports of initial neurological involvement.
View Article and Find Full Text PDFMacrophage Activation Syndrome in a Patient with Systemic Lupus Erythematous Triggered by Tuberculous Meningitis.
Eur J Case Rep Intern Med
December 2024
Internal Medicine, Dubai Health, Dubai, United Arab Emirates.
Background: Hemophagocytic lymphohistiocytosis (HLH), is characterized by systemic uncontrolled inflammation resulting from immune dysregulation secondary to various triggers, including genetics, infections, autoimmune diseases, and malignancies. Macrophage activation syndrome (MAS) is an immune dysregulation phenomenon, in which an underlying rheumatological disease is present. We report a rare, interesting case of a middle-aged female, with a systemic lupus erythematosus (SLE) flare complicated by macrophage activation syndrome (MAS), in which tuberculous meningitis (TBM) was the identified trigger.
View Article and Find Full Text PDFDisseminated tuberculosis masquerading as a psychiatric illness-A case report.
J Family Med Prim Care
December 2024
Department of Medicine, Universiti Teknologi MARA, Puncak Alam, Malaysia, Asia.
Unlabelled: Tuberculosis (TB) can affect any organ, and at times more than one organ in any sequence, in which case it is referred to as disseminated tuberculosis (DTB). We report a patient who presented primarily for psychiatric symptoms of three months' duration, which later turned out to be a case of DTB involving the central nervous system as well as the spine and lungs.
Case Presentation: An elderly lady with subacute onset and worsening behavioural changes of three months' duration was referred for exclusion of organic brain disease.
Opsoclonus Myoclonus Ataxia Syndrome: An Atypical Presentation of Tuberculous Meningitis.
Am J Trop Med Hyg
January 2025
Pediatric Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, Rishikesh, India.
Opsoclonus myoclonus ataxia syndrome (OMAS) is a rare neuroinflammatory disorder that is typically associated with paraneoplastic and postinfectious processes. Opsoclonus myoclonus ataxia syndrome has not been previously reported in association with tuberculous meningitis (TBM). This report presents a unique case in which TBM manifested as OMAS, highlighting the complex interplay between tuberculosis and autoimmune neurological conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!